📣 VC round data is live. Check it out!
- Public Comps
- ICON plc
ICON plc Valuation Multiples
Discover ICON plc's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Pro Medicus, Revvity, Tempus AI, Charles River and more.
ICON plc Overview
About ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Founded
1990
HQ

Employees
41.9K
Website
Sectors
Financials (LTM)
EV
$13B
Valuation Multiples
Start free trialICON plc Financials
ICON plc reported last 12-month revenue of $8B and EBITDA of $1B.
In the same LTM period, ICON plc generated $2B in gross profit, $1B in EBITDA, and $922M in net income.
Revenue (LTM)
ICON plc P&L
In the most recent fiscal year, ICON plc reported revenue of $8B and EBITDA of $2B.
ICON plc is profitable as of last fiscal year, with gross margin of 26%, EBITDA margin of 19%, and net margin of 12%.
Financial data powered by Morningstar, Inc.
ICON plc Stock Performance
ICON plc has current market cap of $11B, and enterprise value of $13B.
Market Cap Evolution
ICON plc's stock price is $138.03.
ICON plc share price increased by 1.4% in the last 30 days, and decreased by 5.1% in the last year.
ICON plc has an EPS (earnings per share) of $12.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13B | $11B | 1.4% | 1.4% | 24.7% | -5.1% | $12.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialICON plc Valuation Multiples
ICON plc trades at 1.7x EV/Revenue multiple, and 9.3x EV/EBITDA.
EV / Revenue (LTM)
ICON plc Financial Valuation Multiples
As of June 2, 2026, ICON plc has market cap of $11B and EV of $13B.
ICON plc has a P/E ratio of 11.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ICON plc Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


ICON plc Margins & Growth Rates
ICON plc decreased revenue by 3% and EBITDA by 13% in the last fiscal year.
In the most recent fiscal year, ICON plc reported gross margin of 26%, EBITDA margin of 19%, and net margin of 12%.
ICON plc Margins
ICON plc Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
ICON plc Operational KPIs
ICON plc's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
ICON plc's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ICON plc's Rule of X is 8% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
ICON plc Competitors
ICON plc competitors include Pro Medicus, Revvity, Tempus AI, Charles River, Wuxi XDC, Eurofins Scientific, Medpace, Solventum, Laurus Labs and Dixon Technologies.
Most ICON plc public comparables operate across Contract Research & Manufacturing, Healthcare Software, Health Data & Analytics, BioTech, B2B SaaS, HealthTech and Vertical SaaS.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 69.8x | 58.5x | 90.2x | 64.2x | |||
| 4.8x | 4.8x | 16.2x | 15.8x | |||
| 8.0x | 7.2x | (1375.8x) | 460.1x | |||
| 2.9x | 2.9x | 12.0x | 11.9x | |||
| 8.8x | 7.7x | 27.5x | 24.5x | |||
| 1.9x | 1.9x | 8.7x | 8.6x | |||
| 4.9x | 4.7x | 21.9x | 21.3x | |||
| 2.1x | 2.2x | 7.0x | 9.5x | |||
This data is available for Pro users. Sign up to see all ICON plc competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by ICON plc
ICON plc has acquired 10 companies to date.
Last acquisition by ICON plc was on February 29th 2024. ICON plc acquired HumanFirst for $13M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by ICON plc
| Description | HumanFirst is a SaaS platform provider for digital endpoints in clinical trials, focusing on digital biomarkers and electronic clinical outcome assessments. Boston-headquartered, it serves 22 of the top 25 pharmaceutical companies, including Pfizer and Novartis, to validate and deploy digital health technologies in over 100 studies. The platform integrates AI-driven analytics with evidence generation tools, supporting respiratory, neurological, and cardiovascular trials. Launched in 2020, HumanFirst facilitates remote patient monitoring and data harmonization compliant with FDA guidelines. | PRA Health Sciences is a Raleigh-based contract research organization delivering full-service clinical development and data management solutions to pharmaceutical and biotechnology firms worldwide. The company operates over 90 offices in North America, Europe, Asia, Latin America, South Africa, Australia, and the Middle East, supporting clinical trials leading to regulatory approvals for more than 85 products since 2000. Acquired by ICON plc in 2021. | MedPass International is a Paris-headquartered contract research organization specializing in medical device regulatory affairs, clinical trials, and reimbursement strategies across Europe. The firm supports clients from concept to market approval with services encompassing CE marking, FDA submissions, and health technology assessments. MedPass assists over 200 medical device companies annually, focusing on cardiovascular, orthopedic, and diagnostic technologies. Its global team operates from offices in France, Germany, and the United Kingdom, providing tailored operational support for breakthrough innovations in interventional devices and implants. | Accellacare is a network of clinical research sites conducting Phase I-IV trials for cardiovascular, endocrinology, and vaccine therapies. With locations in Colorado, Florida, and other US states, it enrolls patients in studies from sponsors like Pfizer and AstraZeneca. Formerly MeDiNova Research, the organization prioritizes participant safety and rapid recruitment. Accellacare advances new treatments through dedicated trial environments. | |
| HQ Country | |||||
| HQ City | San Francisco, CA | Raleigh, NC | Paris | London | |
| Deal Date | 29 Feb 2024 | 24 Feb 2021 | 20 Feb 2020 | 24 May 2019 | |
| Valuation | $13M | $12B | $47M | $54M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all ICON plc acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ICON plc
| When was ICON plc founded? | ICON plc was founded in 1990. |
| Where is ICON plc headquartered? | ICON plc is headquartered in United States. |
| How many employees does ICON plc have? | As of today, ICON plc has over 41K employees. |
| Who is the CEO of ICON plc? | ICON plc's CEO is Steven Cutler. |
| Is ICON plc publicly listed? | Yes, ICON plc is a public company listed on Nasdaq. |
| What is the stock symbol of ICON plc? | ICON plc trades under ICLR ticker. |
| When did ICON plc go public? | ICON plc went public in 1998. |
| Who are competitors of ICON plc? | ICON plc main competitors include Pro Medicus, Revvity, Tempus AI, Charles River, Wuxi XDC, Eurofins Scientific, Medpace, Solventum, Laurus Labs, Dixon Technologies. |
| What is the current market cap of ICON plc? | ICON plc's current market cap is $11B. |
| What is the current revenue of ICON plc? | ICON plc's last 12 months revenue is $8B. |
| What is the current revenue growth of ICON plc? | ICON plc revenue growth (NTM/LTM) is (1%). |
| What is the current EV/Revenue multiple of ICON plc? | Current revenue multiple of ICON plc is 1.7x. |
| What is the current EBITDA of ICON plc? | ICON plc's last 12 months EBITDA is $1B. |
| What is ICON plc's EBITDA margin? | ICON plc's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of ICON plc? | Current EBITDA multiple of ICON plc is 9.3x. |
| What is the current FCF of ICON plc? | ICON plc's last 12 months FCF is $845M. |
| What is ICON plc's FCF margin? | ICON plc's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of ICON plc? | Current FCF multiple of ICON plc is 15.9x. |
| How many companies ICON plc has acquired to date? | As of June 2026, ICON plc has acquired 10 companies. |
| What was the largest acquisition by ICON plc? | $12B acquisition of PRA Health Sciences on 24th February 2021 was the largest M&A ICON plc has done to date. |
| What companies ICON plc acquired? | ICON plc acquired PRA Health Sciences, Aptiv Solutions, Mapi Group, MediMedia Pharma Solutions, PMG Research, Accellacare, Clinical Research Management, MedPass International, MolecularMD, and HumanFirst. |
| In how many companies ICON plc has invested to date? | ICON plc hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to ICON plc
Lists including ICON plc
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


